Oral Regimens for AML Make Strides.

All-oral decitabine-cedazuridine and venetoclax regimen shows promise for AML patients, with potential improvements in treatment options.

• Why it matters: This work addresses the need for effective oral therapies for acute myeloid leukemia (AML), which traditionally rely on intravenous or subcutaneous chemotherapy, often associated with significant side effects and logistical challenges.
• What they did: Researchers conducted two phase I/II trials, ASCERTAIN-V and SAVE, testing an all-oral combination of decitabine-cedazuridine and venetoclax, with revumenib added in the SAVE study.
• The result: Findings suggest this oral regimen could be an effective alternative for AML patients, potentially expanding treatment options and improving patient convenience.